Chronic valproic acid intoxication in epileptology: diagnosis and treatment
https://doi.org/10.14412/2074-2711-2016-2-94-99
Abstract
Valproic acid (VA) is used in epileptology for the basic and additional control of simple and complex focal seizures, absences, generalized tonicclonic seizures, and myoclonus. Information has been recently stored on cases of chronic overdosage of VA due to its blood accumulation. These conditions are described in the use of both high and average therapeutic doses of VA preparations in patients with a genetically determined delay in metabolism. The paper presents current methods for clinical and laboratory diagnosis and correction of chronic intoxication when valproic acid preparations are administered during the prehospital, hospital and rehabilitation phases of treatment. The authors note that a personalized approach is of importance for dose adjustment and prediction of unwanted adverse drug reactions associated with the use of VA preparations.
About the Authors
N. A. Shnaider
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia, Krasnoyarsk
Russian Federation
Russian Federation
1, Partisan Zheleznyak, Krasnoyarsk 660022
D. V. Dmitrenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia, Krasnoyarsk
Russian Federation
Russian Federation
1, Partisan Zheleznyak, Krasnoyarsk 660022
References
1. Кукес ВГ, Бочков НП, редакторы. Клиническая фармакогенетика: Учебное пособие. Москва: ГЭОТАР-Медиа; 2007. 248 с. [Kukes VG, Bochkov NP, editors. Klinicheskaya farmakogenetika: Uchebnoe posobie [Clinical pharmacogenomics: study guide]. Moscow: GEOTAR-Media; 2007. 248 p.]
2. Пилюгина МС. Пути метаболизма препаратов вальпроевой кислоты и карбамазепина. Вестник Клинической больницы №51. 2010;3(10):52-5. [Pilyugina MS. Paths of metabolism of valproic acid drugs and carbamazepine. Vestnik Klinicheskoi bol'nitsy №51. 2010;3(10):52-5. (In Russ.)].
3. Wadzinski J, Franks R, Roane D, et al. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007 Sep-Oct;20(5):499-502.
4. Шнайдер НА, Пилюгина МС, Дмитренко ДВ и др. Структура и частота встречаемости нежелательных лекарственных реакций на фоне приема противоэпилептических препаратов у женщин, больных эпилепсией. Проблемы женского здоровья. 2011;6(2):22-6. [Shnaider NA, Pilyugina MS, Dmitrenko DV, et al. The structure and incidence of adverse drug reactions of antiepileptic drugs in women with epilepsy. Problemy zhenskogo zdorov'ya. 2011;6(2):22-6. (In Russ.)].
5. Graudins A, Aaron CK. Delayed peak serum valproic acid in massive divalproex overdosetreatment with charcoal hemoperfusion. J Toxicol Clin Toxicol. 1996;34(3):335-41.
6. Eyer F, Felgenhauer N, Gempel K, et al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005 Aug;25(4):376-80.
7. https://www.pharmgkb.org/pathway/ PA165964265
8. http://www.drugbank.ca/drugs/DB00313
9. Дмитренко ДВ, Шнайдер НА, Шаповалова ЕА и др. Фармакогенетические особен- ности метаболизма препаратов вальпроевой кислоты: учебное пособие. Красноярск: Оперативная полиграфия; 2015. 75 с. [Dmitrenko DV, Shnaider NA, Shapovalova EA, et al. Farmakogeneticheskie osobennosti metabolizma preparatov val'proevoi kisloty: uchebnoe posobie [Pharmacogenetic features of the metabolism of drugs valproic acid: a tutorial]. Krasnoyarsk: Operativnaya poligrafiya; 2015. 75 p.]
10. Шнайдер НА, Бочанова ЕН, Зырянов СК и др. Использование регистра пациентов с эпилепсией и эпилептическими синдромами для анализа побочных эффектов противоэпилептических препаратов. Современные проблемы науки и образования. 2016;(2):1-6. [Shnaider NA, Bochanova EN, Zyryanov SK, et al. The use of a register of patients with epilepsy and epileptic syndromes for the analysis of side effects of antiepileptic drugs]. Modern problems of science and education. 2016;(2):1-6. (In Russ.)]. http://www.scienceeducation.ru/article/view?id=24254
11. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002;40(6):789-801.
12. Дмитренко ДВ, Шнайдер НА. Исследование полиморфизма гена CYP2C9 у женщин, принимающих вальпроаты. Медицинская генетика. 2015;(10):36-42. [Dmitrenko DV, Shnaider NA. The study of CYP2C9 gene polymorphism in women taking valproates. Meditsinskaya genetika. 2015;(10):36-42. (In Russ.)].
13. Tank JE, Palmer BF. Simultaneous «in series» hemodialysis and hemoperfusion in the management of valproic acid overdose. Am J Kidney Dis. 1993 Aug;22(2):341-4.
14. Meek MF, Broekroelofs J, Yska JP, et al. Valproic acid intoxication: sense and non-sense of haemodialysis. Neth J Med. 2004 Oct;62(9):333-6.
15. Kane SL, Constantiner M, Staubus AE, et al. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother. 2000 Oct;34(10):1146-51.
16. Kay TD, Playford HR, Johnson DW. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol. 2003 Jan;59(1):56-8.
17. Perez A, McKay CA. Role of carnitine in valproic acid toxicity. J Toxicol Clin Toxicol. 2003;41(6):899; author reply 901-2.
18. Ishikura H, Matsuo N, Matsubara M, et al. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol. 1996 Jan-Feb;20(1):55-8.
19. Caraccio TR, Mofenson HC. Carnitine. J Toxicol Clin Toxicol. 2003;41(6):897; author reply 901-2.
20. LoVecchio F, Thole D, Bagnasco T. Delayed absorption of valproic acid, resulting in coma. Acad Emerg Med. 2002 Dec;9(12):1464.
21. Khoo SH, Leyland MJ. Cerebral edema following acute sodium valproate overdose. J Toxicol Clin Toxicol. 1992;30(2):209-14.
22. Налетов АВ, Чурилина АВ, Богатырева ЕВ. Опыт применения препарата «Тиотриазолин» в терапии детей с хроническими запорами. Архив клiнiчноi та експериментальноi медицини. 2011;20(2):168-72. [Naletov AV, Churilina AV, Bogatyreva EV. The experience of use of «Thiotriazoline» in the treatment of children with chronic constipation. Arkhiv klinichnoi ta eksperimental'noi meditsini. 2011;20(2): 168-72. (In Russ.)].
23. Козловский ВИ, Коневалова НЮ, Козловская СП. Новый цитопротектор тиотриазолин. Вестник фармации. 2007;38(4):55-9. [Kozlovskii VI, Konevalova NYu, Kozlovskaya SP. New cytoprotector thiotriazolin. Vestnik farmatsii. 2007;38(4):55-9. (In Russ.)].
24. Савченко МА, Ярмолович ВВ, Власенкова ЕС, Борис МА. Применение тиотриазолина в амбулаторной практике: опыт и перспективы. Медицинские новости. 2013;9(228):69-74. [Savchenko MA, Yarmolovich VV, Vlasenkova ES, Boris MA. Application of thiotriazoline in outpatient practice: experience and perspectives. Meditsinskie novosti. 2013;9(228):69-74. (In Russ.)].
Review
For citations:
Shnaider NA, Dmitrenko DV. Chronic valproic acid intoxication in epileptology: diagnosis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):94-99. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-94-99
Views:
1007
Email this article 